Posted by Michael Wonder on 11 Jun 2020
FDA approves new therapy for rare disease affecting optic nerve, spinal cord
11 June 2020 - Second FDA approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option.
The U.S. FDA today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive).
The effectiveness of Uplizna for the treatment of NMOSD was demonstrated in a clinical study of 230 adult patients that evaluated the efficacy and safety of intravenous Uplizna.
